 | • レポートコード：MRC2-11QY03950 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は神経皮膚性疾患のグローバル市場について調査・分析したレポートです。種類別（結節性硬化症（TS）、神経線維腫症（NF）、スタージーウェーバー症候群、フォンヒッペルリンダウ（VHL）、運動失調-毛細血管拡張性運動失調症（A-T）、その他）市場規模、用途別（病院、診療所、診断センター、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別神経皮膚性疾患の競争状況、市場シェア ・世界の神経皮膚性疾患市場：種類別市場規模 2015年-2020年（結節性硬化症（TS）、神経線維腫症（NF）、スタージーウェーバー症候群、フォンヒッペルリンダウ（VHL）、運動失調-毛細血管拡張性運動失調症（A-T）、その他） ・世界の神経皮膚性疾患市場：種類別市場規模予測 2021年-2026年（結節性硬化症（TS）、神経線維腫症（NF）、スタージーウェーバー症候群、フォンヒッペルリンダウ（VHL）、運動失調-毛細血管拡張性運動失調症（A-T）、その他） ・世界の神経皮膚性疾患市場：用途別市場規模 2015年-2020年（病院、診療所、診断センター、その他） ・世界の神経皮膚性疾患市場：用途別市場規模予測 2021年-2026年（病院、診療所、診断センター、その他） ・北米の神経皮膚性疾患市場分析：米国、カナダ ・ヨーロッパの神経皮膚性疾患市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの神経皮膚性疾患市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の神経皮膚性疾患市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの神経皮膚性疾患市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Johnson & Johnson、Medtronic、Abbott、Novartis、Roche、Sanofi、Takeda、Allergan、Syneron Medical、Aleva Neurotherapeutics、Abbott Laboratories、Bausch Health ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
The neurocutaneous syndrome is a group of neurologic disorders of brain, spine, and the peripheral nervous system. These diseases are lifelong conditions that may induce a tumor growth inside the skin, organs, skeletal bones, brain, and spinal cord. These disorders are usually genetic and arise due to abnormal cell development at the embryo stage. The result is characterized by the development of tumors in various parts of the body. Even though some can be diagnosed at birth, most of them do not display symptoms until late.
The Americas region accounted for the largest market share of the global neurocutaneous disorder market owing to the increasing awareness about genetic disorders along with the growing number of drug and medical service providers.
Market Analysis and Insights: Global Neurocutaneous Disorder Market
The global Neurocutaneous Disorder market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Neurocutaneous Disorder Scope and Market Size
Neurocutaneous Disorder market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Neurocutaneous Disorder market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Johnson & Johnson
Medtronic
Abbott
Novartis
Roche
Sanofi
Takeda
Allergan
Syneron Medical
Aleva Neurotherapeutics
Abbott Laboratories
Bausch Health
Market segment by Type, the product can be split into
Tuberous Sclerosis (TS)
Neurofibromatosis (NF)
Sturge-Weber Syndrome
Von Hippel-Lindau (VHL)
Ataxia-Telangiectasia (A-T)
Others
Market segment by Application, split into
Hospitals
Clinics
Diagnostic Centers
Others
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neurocutaneous Disorder Revenue
1.4 Market by Type
1.4.1 Global Neurocutaneous Disorder Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Tuberous Sclerosis (TS)
1.4.3 Neurofibromatosis (NF)
1.4.4 Sturge-Weber Syndrome
1.4.5 Von Hippel-Lindau (VHL)
1.4.6 Ataxia-Telangiectasia (A-T)
1.4.7 Others
1.5 Market by Application
1.5.1 Global Neurocutaneous Disorder Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Diagnostic Centers
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Neurocutaneous Disorder Market Perspective (2015-2026)
2.2 Global Neurocutaneous Disorder Growth Trends by Regions
2.2.1 Neurocutaneous Disorder Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Neurocutaneous Disorder Historic Market Share by Regions (2015-2020)
2.2.3 Neurocutaneous Disorder Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Neurocutaneous Disorder Market Growth Strategy
2.3.6 Primary Interviews with Key Neurocutaneous Disorder Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Neurocutaneous Disorder Players by Market Size
3.1.1 Global Top Neurocutaneous Disorder Players by Revenue (2015-2020)
3.1.2 Global Neurocutaneous Disorder Revenue Market Share by Players (2015-2020)
3.1.3 Global Neurocutaneous Disorder Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Neurocutaneous Disorder Market Concentration Ratio
3.2.1 Global Neurocutaneous Disorder Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Neurocutaneous Disorder Revenue in 2019
3.3 Neurocutaneous Disorder Key Players Head office and Area Served
3.4 Key Players Neurocutaneous Disorder Product Solution and Service
3.5 Date of Enter into Neurocutaneous Disorder Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Neurocutaneous Disorder Historic Market Size by Type (2015-2020)
4.2 Global Neurocutaneous Disorder Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Neurocutaneous Disorder Market Size by Application (2015-2020)
5.2 Global Neurocutaneous Disorder Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Neurocutaneous Disorder Market Size (2015-2020)
6.2 Neurocutaneous Disorder Key Players in North America (2019-2020)
6.3 North America Neurocutaneous Disorder Market Size by Type (2015-2020)
6.4 North America Neurocutaneous Disorder Market Size by Application (2015-2020)
7 Europe
7.1 Europe Neurocutaneous Disorder Market Size (2015-2020)
7.2 Neurocutaneous Disorder Key Players in Europe (2019-2020)
7.3 Europe Neurocutaneous Disorder Market Size by Type (2015-2020)
7.4 Europe Neurocutaneous Disorder Market Size by Application (2015-2020)
8 China
8.1 China Neurocutaneous Disorder Market Size (2015-2020)
8.2 Neurocutaneous Disorder Key Players in China (2019-2020)
8.3 China Neurocutaneous Disorder Market Size by Type (2015-2020)
8.4 China Neurocutaneous Disorder Market Size by Application (2015-2020)
9 Japan
9.1 Japan Neurocutaneous Disorder Market Size (2015-2020)
9.2 Neurocutaneous Disorder Key Players in Japan (2019-2020)
9.3 Japan Neurocutaneous Disorder Market Size by Type (2015-2020)
9.4 Japan Neurocutaneous Disorder Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Neurocutaneous Disorder Market Size (2015-2020)
10.2 Neurocutaneous Disorder Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Neurocutaneous Disorder Market Size by Type (2015-2020)
10.4 Southeast Asia Neurocutaneous Disorder Market Size by Application (2015-2020)
11 India
11.1 India Neurocutaneous Disorder Market Size (2015-2020)
11.2 Neurocutaneous Disorder Key Players in India (2019-2020)
11.3 India Neurocutaneous Disorder Market Size by Type (2015-2020)
11.4 India Neurocutaneous Disorder Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Neurocutaneous Disorder Market Size (2015-2020)
12.2 Neurocutaneous Disorder Key Players in Central & South America (2019-2020)
12.3 Central & South America Neurocutaneous Disorder Market Size by Type (2015-2020)
12.4 Central & South America Neurocutaneous Disorder Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Neurocutaneous Disorder Introduction
13.1.4 Pfizer Revenue in Neurocutaneous Disorder Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Details
13.2.2 Johnson & Johnson Business Overview
13.2.3 Johnson & Johnson Neurocutaneous Disorder Introduction
13.2.4 Johnson & Johnson Revenue in Neurocutaneous Disorder Business (2015-2020)
13.2.5 Johnson & Johnson Recent Development
13.3 Medtronic
13.3.1 Medtronic Company Details
13.3.2 Medtronic Business Overview
13.3.3 Medtronic Neurocutaneous Disorder Introduction
13.3.4 Medtronic Revenue in Neurocutaneous Disorder Business (2015-2020)
13.3.5 Medtronic Recent Development
13.4 Abbott
13.4.1 Abbott Company Details
13.4.2 Abbott Business Overview
13.4.3 Abbott Neurocutaneous Disorder Introduction
13.4.4 Abbott Revenue in Neurocutaneous Disorder Business (2015-2020)
13.4.5 Abbott Recent Development
13.5 Novartis
13.5.1 Novartis Company Details
13.5.2 Novartis Business Overview
13.5.3 Novartis Neurocutaneous Disorder Introduction
13.5.4 Novartis Revenue in Neurocutaneous Disorder Business (2015-2020)
13.5.5 Novartis Recent Development
13.6 Roche
13.6.1 Roche Company Details
13.6.2 Roche Business Overview
13.6.3 Roche Neurocutaneous Disorder Introduction
13.6.4 Roche Revenue in Neurocutaneous Disorder Business (2015-2020)
13.6.5 Roche Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview
13.7.3 Sanofi Neurocutaneous Disorder Introduction
13.7.4 Sanofi Revenue in Neurocutaneous Disorder Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Takeda
13.8.1 Takeda Company Details
13.8.2 Takeda Business Overview
13.8.3 Takeda Neurocutaneous Disorder Introduction
13.8.4 Takeda Revenue in Neurocutaneous Disorder Business (2015-2020)
13.8.5 Takeda Recent Development
13.9 Allergan
13.9.1 Allergan Company Details
13.9.2 Allergan Business Overview
13.9.3 Allergan Neurocutaneous Disorder Introduction
13.9.4 Allergan Revenue in Neurocutaneous Disorder Business (2015-2020)
13.9.5 Allergan Recent Development
13.10 Syneron Medical
13.10.1 Syneron Medical Company Details
13.10.2 Syneron Medical Business Overview
13.10.3 Syneron Medical Neurocutaneous Disorder Introduction
13.10.4 Syneron Medical Revenue in Neurocutaneous Disorder Business (2015-2020)
13.10.5 Syneron Medical Recent Development
13.11 Aleva Neurotherapeutics
10.11.1 Aleva Neurotherapeutics Company Details
10.11.2 Aleva Neurotherapeutics Business Overview
10.11.3 Aleva Neurotherapeutics Neurocutaneous Disorder Introduction
10.11.4 Aleva Neurotherapeutics Revenue in Neurocutaneous Disorder Business (2015-2020)
10.11.5 Aleva Neurotherapeutics Recent Development
13.12 Abbott Laboratories
10.12.1 Abbott Laboratories Company Details
10.12.2 Abbott Laboratories Business Overview
10.12.3 Abbott Laboratories Neurocutaneous Disorder Introduction
10.12.4 Abbott Laboratories Revenue in Neurocutaneous Disorder Business (2015-2020)
10.12.5 Abbott Laboratories Recent Development
13.13 Bausch Health
10.13.1 Bausch Health Company Details
10.13.2 Bausch Health Business Overview
10.13.3 Bausch Health Neurocutaneous Disorder Introduction
10.13.4 Bausch Health Revenue in Neurocutaneous Disorder Business (2015-2020)
10.13.5 Bausch Health Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Neurocutaneous Disorder Key Market Segments
Table 2. Key Players Covered: Ranking by Neurocutaneous Disorder Revenue
Table 3. Ranking of Global Top Neurocutaneous Disorder Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Neurocutaneous Disorder Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tuberous Sclerosis (TS)
Table 6. Key Players of Neurofibromatosis (NF)
Table 7. Key Players of Sturge-Weber Syndrome
Table 8. Key Players of Von Hippel-Lindau (VHL)
Table 9. Key Players of Ataxia-Telangiectasia (A-T)
Table 10. Key Players of Others
Table 11. Global Neurocutaneous Disorder Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 12. Global Neurocutaneous Disorder Market Size by Regions (US$ Million): 2020 VS 2026
Table 13. Global Neurocutaneous Disorder Market Size by Regions (2015-2020) (US$ Million)
Table 14. Global Neurocutaneous Disorder Market Share by Regions (2015-2020)
Table 15. Global Neurocutaneous Disorder Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 16. Global Neurocutaneous Disorder Market Share by Regions (2021-2026)
Table 17. Market Top Trends
Table 18. Key Drivers: Impact Analysis
Table 19. Key Challenges
Table 20. Neurocutaneous Disorder Market Growth Strategy
Table 21. Main Points Interviewed from Key Neurocutaneous Disorder Players
Table 22. Global Neurocutaneous Disorder Revenue by Players (2015-2020) (Million US$)
Table 23. Global Neurocutaneous Disorder Market Share by Players (2015-2020)
Table 24. Global Top Neurocutaneous Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurocutaneous Disorder as of 2019)
Table 25. Global Neurocutaneous Disorder by Players Market Concentration Ratio (CR5 and HHI)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Neurocutaneous Disorder Product Solution and Service
Table 28. Date of Enter into Neurocutaneous Disorder Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 31. Global Neurocutaneous Disorder Market Size Share by Type (2015-2020)
Table 32. Global Neurocutaneous Disorder Revenue Market Share by Type (2021-2026)
Table 33. Global Neurocutaneous Disorder Market Size Share by Application (2015-2020)
Table 34. Global Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 35. Global Neurocutaneous Disorder Market Size Share by Application (2021-2026)
Table 36. North America Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 37. North America Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 38. North America Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 39. North America Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 40. North America Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 41. North America Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 42. Europe Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 43. Europe Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 44. Europe Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 45. Europe Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 46. Europe Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 47. Europe Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 48. China Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 49. China Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 50. China Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 51. China Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 52. China Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 53. China Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 54. Japan Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 55. Japan Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 56. Japan Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 57. Japan Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 58. Japan Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 59. Japan Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 60. Southeast Asia Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 61. Southeast Asia Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 62. Southeast Asia Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 63. Southeast Asia Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 64. Southeast Asia Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 65. Southeast Asia Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 66. India Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 67. India Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 68. India Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 69. India Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 70. India Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 71. India Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 72. Central & South America Key Players Neurocutaneous Disorder Revenue (2019-2020) (Million US$)
Table 73. Central & South America Key Players Neurocutaneous Disorder Market Share (2019-2020)
Table 74. Central & South America Neurocutaneous Disorder Market Size by Type (2015-2020) (Million US$)
Table 75. Central & South America Neurocutaneous Disorder Market Share by Type (2015-2020)
Table 76. Central & South America Neurocutaneous Disorder Market Size by Application (2015-2020) (Million US$)
Table 77. Central & South America Neurocutaneous Disorder Market Share by Application (2015-2020)
Table 78. Pfizer Company Details
Table 79. Pfizer Business Overview
Table 80. Pfizer Product
Table 81. Pfizer Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 82. Pfizer Recent Development
Table 83. Johnson & Johnson Company Details
Table 84. Johnson & Johnson Business Overview
Table 85. Johnson & Johnson Product
Table 86. Johnson & Johnson Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 87. Johnson & Johnson Recent Development
Table 88. Medtronic Company Details
Table 89. Medtronic Business Overview
Table 90. Medtronic Product
Table 91. Medtronic Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 92. Medtronic Recent Development
Table 93. Abbott Company Details
Table 94. Abbott Business Overview
Table 95. Abbott Product
Table 96. Abbott Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 97. Abbott Recent Development
Table 98. Novartis Company Details
Table 99. Novartis Business Overview
Table 100. Novartis Product
Table 101. Novartis Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 102. Novartis Recent Development
Table 103. Roche Company Details
Table 104. Roche Business Overview
Table 105. Roche Product
Table 106. Roche Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 107. Roche Recent Development
Table 108. Sanofi Company Details
Table 109. Sanofi Business Overview
Table 110. Sanofi Product
Table 111. Sanofi Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 112. Sanofi Recent Development
Table 113. Takeda Business Overview
Table 114. Takeda Product
Table 115. Takeda Company Details
Table 116. Takeda Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 117. Takeda Recent Development
Table 118. Allergan Company Details
Table 119. Allergan Business Overview
Table 120. Allergan Product
Table 121. Allergan Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 122. Allergan Recent Development
Table 123. Syneron Medical Company Details
Table 124. Syneron Medical Business Overview
Table 125. Syneron Medical Product
Table 126. Syneron Medical Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 127. Syneron Medical Recent Development
Table 128. Aleva Neurotherapeutics Company Details
Table 129. Aleva Neurotherapeutics Business Overview
Table 130. Aleva Neurotherapeutics Product
Table 131. Aleva Neurotherapeutics Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 132. Aleva Neurotherapeutics Recent Development
Table 133. Abbott Laboratories Company Details
Table 134. Abbott Laboratories Business Overview
Table 135. Abbott Laboratories Product
Table 136. Abbott Laboratories Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 137. Abbott Laboratories Recent Development
Table 138. Bausch Health Company Details
Table 139. Bausch Health Business Overview
Table 140. Bausch Health Product
Table 141. Bausch Health Revenue in Neurocutaneous Disorder Business (2015-2020) (Million US$)
Table 142. Bausch Health Recent Development
Table 143. Research Programs/Design for This Report
Table 144. Key Data Information from Secondary Sources
Table 145. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurocutaneous Disorder Market Share by Type: 2020 VS 2026
Figure 2. Tuberous Sclerosis (TS) Features
Figure 3. Neurofibromatosis (NF) Features
Figure 4. Sturge-Weber Syndrome Features
Figure 5. Von Hippel-Lindau (VHL) Features
Figure 6. Ataxia-Telangiectasia (A-T) Features
Figure 7. Others Features
Figure 8. Global Neurocutaneous Disorder Market Share by Application: 2020 VS 2026
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Diagnostic Centers Case Studies
Figure 12. Others Case Studies
Figure 13. Neurocutaneous Disorder Report Years Considered
Figure 14. Global Neurocutaneous Disorder Market Size YoY Growth 2015-2026 (US$ Million)
Figure 15. Global Neurocutaneous Disorder Market Share by Regions: 2020 VS 2026
Figure 16. Global Neurocutaneous Disorder Market Share by Regions (2021-2026)
Figure 17. Porter's Five Forces Analysis
Figure 18. Global Neurocutaneous Disorder Market Share by Players in 2019
Figure 19. Global Top Neurocutaneous Disorder Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurocutaneous Disorder as of 2019
Figure 20. The Top 10 and 5 Players Market Share by Neurocutaneous Disorder Revenue in 2019
Figure 21. North America Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Europe Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. China Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Japan Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Southeast Asia Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. India Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. Central & South America Neurocutaneous Disorder Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Bottom-up and Top-down Approaches for This Report
Figure 29. Data Triangulation
Figure 30. Key Executives Interviewed
自閉症スペクトラム障害（ASD）治療の世界市場（～2026年） Autism spectrum disorder (ASD) refers to a group of complex neurodevelopment disorders characterized by repetitive and characteristic patterns of behavior and difficulties with social communication and interaction. According to CDC statistics, 1 in every 68 children suffers with autism. Innovative d…- 甲状腺障害治療の世界市場（～2026年） Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing. Globally, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. Hyperthyroidism and hypothyroidism affect major…
- 脂質異常症治療の世界市場（～2026年） Lipid disorder means the people high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides,. Several biopharma companies are focusing on developing effective solutions for treating lipid disorders. Companies involved in lipid disorder treatment market include Teva Phar…
- ENT疾患治療の世界市場（～2026年） ENT is a medical abbreviation for ears, nose and throat. Major factor contributing to growth of the global ENT disorder treatment market includes increasing pollution. Market Analysis and Insights: Global ENT Disorder Treatment Market The global ENT Disorder Treatment market size is projected to rea…
- 心的外傷後ストレス障害（PTSD）治療薬の世界市場（～2026年） Post-Traumatic Stress Disorder (PTSD) therapeutics include drugs that are used in the treatment of PTSD. The rising prevalence of PTSD to be one of the primary growth factors for the post-traumatic stress disorder (PTSD) therapeutics market. Market Analysis and Insights: Global Post-Traumatic Stress…